Xenetic Biosciences, Inc. (XBIO) Stock Forecast
XBIO analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $40.00 average of analyst targets
- Upside to target
- +1,910.1% from the latest close
- Next earnings
- November 11, 2026
- 52-week range
- $1.99 – $4.67
XBIO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
XBIO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$3.32 | −$3.32 | −$3.32 | −$1.58 | −110.1% | 1 |
| Next fiscal year (2027) | −$0.34 | −$0.34 | −$0.34 | −$3.32 | +89.8% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
XBIO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current fiscal year (2026) | $0 | $0 | $0 | +2.4% | — |
| Next fiscal year (2027) | $1.9M | $1.9M | $1.9M | −16.7% | 1 |
XBIO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
XBIO revenue: reported and forecast
XBIO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$4.46 | −$3.32 | −$3.32 | −$3.32 | −$3.32 | −25.6% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.43 | −$0.34 | −$0.34 | −$0.34 | −$0.34 | −20.9% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
XBIO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; XBIO beat in 8 of 10.
What analysts expect from XBIO
The average price target is $40.00, 1,910.1% above the latest close of $1.99. Analysts expect earnings of −$3.32 per share for 2026, −110.1% from a year earlier. For 2027 the average estimate is −$0.34 per share on revenue of $1.9 million. Xenetic Biosciences beat the EPS estimate in 8 of the last 10 quarters.
Related: XBIO income statement, XBIO key metrics, XBIO chart. See the XBIO stock overview for the latest quote and news.
XBIO forecast FAQ
What is Xenetic Biosciences's price target?
The average analyst price target for Xenetic Biosciences is $40.00, 1,910.1% above the latest close of $1.99.
What is Xenetic Biosciences's EPS forecast?
Analysts forecast −$3.32 per share for 2026 (range −$3.32 to −$3.32); for 2027 the estimate is −$0.34.
When does Xenetic Biosciences report earnings?
Xenetic Biosciences is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
Does Xenetic Biosciences usually beat earnings estimates?
Xenetic Biosciences reported EPS at or above the analyst estimate in 8 of the last 10 quarters.